Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study

S. Zweijpfenning (Nijmegen, Netherlands), S. Kops (Nijmegen, Netherlands), M. Boeree (Nijmegen, Netherlands), S. Kuipers (Nijmegen, Netherlands), J. Van Ingen (Nijmegen, Netherlands), W. Hoefsloot (Nijmegen, Netherlands), C. Magis-Escurra (Nijmegen, Netherlands)

Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Session: Tuberculosis and non-TB mycobacterial infection I
Session type: Oral Presentation
Number: 3821

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Zweijpfenning (Nijmegen, Netherlands), S. Kops (Nijmegen, Netherlands), M. Boeree (Nijmegen, Netherlands), S. Kuipers (Nijmegen, Netherlands), J. Van Ingen (Nijmegen, Netherlands), W. Hoefsloot (Nijmegen, Netherlands), C. Magis-Escurra (Nijmegen, Netherlands). Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study. 3821

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: